Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Notes Payables (2020 - 2021)

Inhibikase Therapeutics (IKT) has disclosed Notes Payables for 2 consecutive years, with $248911.0 as the latest value for Q4 2021.

  • On a quarterly basis, Notes Payables fell 21.97% to $248911.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $248911.0, a 21.97% decrease, with the full-year FY2021 number at $248911.0, down 21.97% from a year prior.
  • Notes Payables was $248911.0 for Q4 2021 at Inhibikase Therapeutics, roughly flat from $248911.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.2 million in Q1 2021 to a low of $248911.0 in Q2 2021.